Is Amondys 45 (casimersen) currently available?
Amondys 45 is an antisense therapy used for Duchenne muscular dystrophy (DMD) with a confirmed mutation amenable to exon 45 skipping. Availability depends on where you are located and whether the prescriber can arrange access through the product’s distribution and any required reimbursement/coverage steps. Public sources provided here do not include country-by-country supply status or live inventory updates.
How do patients typically get Amondys 45 if it isn’t on local shelves?
Clinics usually obtain Amondys 45 through specialist pharmacy distribution or hospital/infusion channels, but the exact pathway varies by country and payer. In many systems, patients can be delayed by prior authorization, documentation of the DMD mutation (exon 45 amenability), and scheduling for intravenous infusions.
What can delay access or cause shortages?
Even when a drug is “available,” delays commonly come from:
Authorization and coverage requirements.
Genetic testing turnaround time needed to confirm exon 45 skipping eligibility.
Infusion center scheduling and staffing.
Supply-chain limitations that can affect time-to-treatment even without a formal “discontinuation.”
What to do if you can’t get Amondys 45 right now
The fastest route is usually to ask the treating neuromuscular team these points:
Who is the dispensing channel (specialty pharmacy vs. infusion site supply) in your region?
What documentation is required for authorization (including the specific exon 45 mutation result)?
What is the expected lead time from ordering to first infusion?
Whether there is an alternative access pathway if your payer rejects the first request.
Are there other exon 45–skipping options (if Amondys 45 is not reachable)?
If access problems persist, clinicians may discuss whether another therapy fits the patient’s mutation and local guidelines, but “exon 45 skipping” eligibility is mutation-specific, so substitution is not always possible.
Quick clarifying questions so I can give a precise availability answer
1) What country (and state/province) are you in?
2) Are you asking about availability for a patient, for a clinic/pharmacy ordering, or for research/clinical use?
3) Do you need “in stock now,” or information about how to start the access process (prior auth, specialist pharmacy, infusion scheduling)?
If you share your location, I can tailor the answer to the most relevant access/distribution route and typical timelines for that region.